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Abstract
Advanced colorectal cancer (CRC) consensus molecular subtype 4 (CMS4) or CRC with a low immunoscore is associated
with shorter survival times. Non-metastatic CRC with microsatellite instability (MSI) is associated with a lower risk of
recurrence. We evaluated outcome (lymph node metastases [LNM] or cancer recurrence) in these tumor subtypes in patients
with surgically-removed non-pedunculated T1 CRC by performing a multicenter case-cohort study. We included all patients
in 13 hospitals in the Netherlands from 2000–2014 (n= 651). We randomly selected a subgroup of patients (n= 223) and all
patients with LNM or recurrence (n= 63), and median follow-up of 44 months. We centrally reviewed tumor-slides, and
constructed and immunostained tissue microarrays determining MSI, CMS (MSI/CMS1, CMS2/3, or CMS4), and
immunoscore (I-low/I-high). We used weighted Cox proportional hazard models to evaluate the association of MSI, CMS,
and immunoscore with LNM or recurrence, adjusting for conventional histologic risk factors. In the randomly selected
subgroup of patients, 7.1% of tumors were MSI/CMS1, 91.0% CMS2/3, 1.8% CMS4, and 25% I-low. In the case-cohort,
patients with CMS4 tumors had an increased risk for LNM or recurrence compared with patients with tumors of other CMSs
(adjusted hazard ratio [HR], 3.97; 95% CI, 1.12–14.06; P= 0.03). Albeit not significant, tumors with MSI had a lower risk
for LNM or recurrence than other tumor subtypes (adjusted HR, 0.52; 95% CI, 0.12–2.30; P= 0.39), whereas tumors with a
low immunoscore had an increased risk for LNM or recurrence (adjusted HR, 1.30; 95% CI, 0.68–2.48; P= 0.43). In
conclusion, in a case-cohort study of patients with non-pedunculated T1 CRC, MSI, and immunoscore were not significantly
associated with adverse outcome after surgery. CMS4 substantially increased the risk of adverse outcome. However, CMS4
is rare in T1 CRCs, limiting its value for determining the risk in patients.
Introduction
The prognosis and therapeutic decision making in patients
with colorectal cancer (CRC) rely on the TNM classifica-
tion, concerning tumor invasion and metastasis [1].
Recently, two new promising prognostic molecular-based
classification systems for CRC have been developed [2].
First, an international consortium has evaluated genome-
wide gene-expression data to classify patients into four
consensus molecular subtypes (CMS) [3]. CMS1, 13% of
CRCs, represents immune-active tumors with high-
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mutational load, Microsatellite instability (MSI) or BRAF-
mutations, and has been recognized as a favorable prog-
nostic subtype in early-stage CRC [4]. CMS2, the canonical
type and comprising 37% of CRCs, is characterized by
activated WNT- and MYC-pathways, high somatic copy-
number alterations, and increased EGFR expression with a
mutated TP53 gene. CMS3, the metabolic type and com-
prising 13% of CRCs, is characterized by low somatic
copy-number alterations, KRAS mutations, and elevated
metabolic signatures. CMS4, representing 23% of CRC, is
characterized by tumors with epithelial-mesenchymal tran-
sition, TGF-beta pathway, and stromal activation. CMS4 is
identified as a subtype with a significantly worse relapse-
free and overall survival of 62 and 60%, respectively [3].
Furthermore, stage III tumors with CMS4 have no benefit
from adjuvant therapy such as FOLFOX and they also seem
resistant to anti-EGFR therapy [5, 6]. A residual group of
13% represents unclassified patients or patients with a
mixed subtype [3, 7].
Second, the immunoscore, focusing on infiltrating
lymphocytes rather than the tumor cells was developed [8].
A low density of CD3 and CD8 T-cells infiltrating the
tumor’s center (TC) and invasive margin (IM), i.e., a low
immunoscore, has been associated with a worse prognosis
in patients with CRC [9, 10]. However, these promising
risk stratification scores have been developed and vali-
dated in patients with mostly advanced tumor stages
(T2–T4) or lymph node or distant metastasis (stage III or
IV), whereas their prevalence and relevance in T1 CRC are
unknown [11]. Risk stratification in T1 CRC (both ped-
unculated and non-pedunculated) is currently based on
conventional histologic markers, such as poor differ-
entiation, lymphovascular invasion, deep submucosal
invasion, and tumor budding. The therapeutic decision to
perform additional oncologic surgery is based on these
markers, but due to low specificity, this leads to unne-
cessary surgery for patients classified as high-risk but
without actual lymph node metastasis (LNM) being pre-
sent (false positives) [12–14]. If the newer classification
systems, CMS and immunoscore, are proven useful in
patients with T1 CRC, they could enable organ preserva-
tion in selected patients.
In this large multicenter cohort study of patients with
non-pedunculated T1 CRC, we aimed to evaluate the fre-
quency distribution of Microsatellite (MS)-status, CMS, and
immunoscore. Furthermore, we assessed the association
with currently used histologic markers for T1 CRC. Finally,
we evaluated whether these molecular- and immune-based
scores could be of clinical value in the selection of high-risk
patients, based on their prediction of an adverse outcome
(LNM or recurrence).
Materials and methods
Study design and source population
A total of 13 Dutch hospitals (1 academic, 12 non-aca-
demic) participated in this multicenter T1 CRC registration
cohort study of the Dutch T1 CRC Working Group. This
cohort consists of all patients diagnosed with T1 CRC
between 2000 and 2014, as identified by the Netherlands
Cancer Registry. All medical records were reviewed, and
exclusion criteria as defined previously were applied (i.e.,
hereditary predisposition for CRC, inflammatory bowel
disease, synchronous CRC, non-CRC related death within 1
year, non-adenocarcinoma, neo-adjuvant radiotherapy, and
missing reports). The definition for morphology was based
on the endoscopist’s judgment prior to resection, as pre-
sumed morphology can be altered by resection techniques
or fixation procedures. Tumors were considered peduncu-
lated when the presence of a stalk was reported or when a
tumor was classified as Paris 0-1p. T1 CRCs with ped-
unculated or unknown morphology were excluded, as they
harbor lower risks for LNM and recurrence compared with
non-pedunculated T1 CRCs [15]. The remaining group of
T1 CRCs was classified as non-pedunculated and consisted
of sessile or flat tumors. We selected all patients with
known lymph node status after surgical resection, resulting
in a cohort of 651 patients with non-pedunculated T1 CRC.
Patients were either treated with an oncologic surgical
resection without a prior attempt of a curative endoscopic
resection (primary surgical resection, n= 471) or surgery
after an endoscopic resection had been performed (sec-
ondary surgical resection, n= 180). All included cases had
negative resection margins (R0).
This study was approved by the Medical Ethics Review
Committee of the University Medical Center Utrecht
(approval for data-collection, reference number: 15-487;
approval for histologic assessment, reference number 15-
716), and performed in accordance with the Helsinki
Declaration.
Case-cohort approach
We adopted a case-cohort approach in which we selected all
patients with an endpoint of interest (LNM and/or recur-
rence) during follow-up and a random 50% subgroup from
the full cohort at baseline (Fig. 1). This approach has all the
benefits of a regular cohort approach for prognostic factor
analysis but is more efficient as fewer samples need
assessment for tumor markers. Due to the low number of
events for each individual outcome, we chose a composite
endpoint ‘adverse outcome’, defined as the presence of
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LNM in the resection specimen and/or recurrent cancer
during follow-up. Both LNM and recurrence are relevant
outcomes to identify those patients who will benefit from a
surgical resection. Distant recurrence was defined as
metastasis to extracolonic organs confirmed with imaging or
histology. Local recurrence was defined as malignant tissue
at the site of the anastomosis. In the subgroup, we assessed
the distribution of MS-status, CMS, and immunoscore, and
their association with conventional histologic risk factors.
The case-cohort set was used to evaluate the prognostic
value of these molecular and immune-based classifications.
The follow-up period started at the time of diagnosis and
finished at 5 years, date of recurrence, death, or last date of
follow-up. Adverse outcomes (LNM and/or recurrent can-
cer) were treated as events with LNM at baseline being
analyzed as an event at 0.01 months.
Pathology review
The hematoxylin-eosin (H&E) slides and formalin-fixed
paraffin-embedded (FFPE) tumor tissue blocks of the case-
cohort set were collected. Two expert pathologists (ML &
GJO) both blinded for the clinical characteristics, patient
outcome, and the original histologic report reviewed the
H&E slides to confirm the diagnosis of T1 CRC. Patients
were excluded if T1 CRC (defined as invasion through the
muscularis mucosae and into, but not beyond, the sub-
mucosa) could not be confirmed [1]. Next, the H&E slides
were reviewed for the conventional histologic risk factors
(i.e., differentiation grade, lymphovascular invasion, inva-
sion depth, and tumor budding) by one pathologist (ML).
The grade of tumor differentiation was assessed according
to the World Health Organization classification of tumors
[16]. Deep invasion was defined as invasion depth ≥1000
μm or Kikuchi level SM2-3. If the muscularis mucosae
could be identified, submucosal depth was measured with
the muscularis mucosae used as baseline. When the mus-
cularis mucosae could not be identified, submucosal depth
was measured from the surface of the tumor at the site of
invasion, as described previously [17]. Lymphovascular
invasion was defined as the presence of cancer cells within
endothelial-lined channels [16]. Tumor budding was mea-
sured, defined and scored using the standardized, evidence-
based method for tumor budding assessment as described
previously: a cancer cell nest consisting of 1 or <5 cells that
infiltrates the interstitium at the invasive margin of the
tumor; after selecting one field where budding is the most
intensive, the number of buds is counted in a field mea-
suring 0.785 mm². Depending on the number of buds, the
grade of budding is defined as grade 1 (0–4 buds), grade 2
(5–9 buds), or grade 3 (>10 buds). Grade 1 is considered
low-grade tumor budding, whereas grades 2 and 3 are
considered high-grade tumor budding [18].
Tissue microarray (TMA)
For each tumor specimen, H&E slides containing tumor
center (TC) and invasive margin (IM) regions were selected
(Fig. 2a). For each region, three cores (diameter: 0.6 mm)
were punched out and set into a recipient paraffin block
using an automated tissue microarrayer (TMA Grand
Master 3D Histech, Sysmex) (Fig. 2b). In order to minimize
batch effects, patients with and without events were mixed
on the TMA-blocks.
Immunohistochemistry (IHC)
Tumors were stratified in different consensus-molecular
subtypes with the use of an IHC-based classifier as devel-
oped and validated by Trinh et al. [19]. TMA-blocks were
cut into 4-μm-thick sections. CMS1 patients were first
grouped using MS-status, identified with antibodies against
MLH1 (1:10; Pharmingen, G168-15), MSH2 (RTU; Cell-
marque, G219-1129), MSH6 (1:200; Abcam; ERP3945)
and PMS2 (1:25; Dako, EP51). To further distinguish
CMS2/CMS3 from CMS4 patients, a panel of five IHC
Fig. 1 Flowchart of patient
inclusion. The subgroup
consisted of a random
subsample (50%) from the full
cohort. The case-cohort set
consisted of the random
subgroup and any additional
cases from the full cohort that
met the composite endpoint
(lymph node metastasis or
recurrent cancer). Five patients
with LNM also developed
recurrent cancer. CRC colorectal
carcinoma, IM invasive margin,
TC tumor center, LNM lymph
node metastasis.
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stains was used with antibodies against: CDX2 (1:200;
Immunologic; EPR2764Y), FRMD6 (1:500; Sigma;
HPA001297), HTR2B (1:75; Sigma; HPA012867), ZEB1
(1:500; Sigma; HPA027524), and Pancytokeratin (1:500;
Thermo Scientific; AE1/AE3). Tumors were stratified in
different immune-subtypes by IHC with antibodies against
CD3 (1:100; Dako) and CD8 (1:100, Dako; CD8/144B) as
proposed by Galon et al. [8]. MLH1, MSH2, MSH6, PMS2,
CDX2, Pancytokeratin, CD3, and CD8 were stained with an
automated slide staining system (Ventana Bench Mark
Ultra, Roche). FRMD6, HTR2B, and ZEB1 were stained
manually as described previously [19].
Determining MSI, CMS, and Immunoscore by
immunohistochemistry
Immunostained TMA slides were scanned at ×40 magnifi-
cations (NanoZoomer-XR, Hamamatsu), (Fig. 2c–e). CMS1
patients were first grouped using MS-status, as determined
by two pathologists (LB and GJO) as presence or loss of
expression of (one of) the mismatch repair proteins MLH1,
MSH2, MSH6 and PMS2. The other five CMS-stainings
were assessed by digital image analysis. We distinguished
CMS2/3 from CMS4 tumors using an automated image
analysis approach, whereby digital images of TMA cores
were segmented and quantitated as previously described
[19]. A random forest probability score was calculated for
each core and cores with a score >60% were classified as
mesenchymal. At least half the cores were required to be
mesenchymal to consider a tumor CMS4 (a detailed
description can be found in the Supplementary Methods).
We distinguished immune-subtypes by determining the
density (number of positive cells/surface area analyzed) of
CD3- and CD8-expressing lymphocytes within each of the
tissue compartments (TC and IM). This was done with
QuPath image analysis (Fig. 2d) [20]. To define the
immunoscore per patient we followed the steps as described
in the paper by Pagès et al. [9], but, because no cut-off
values are provided in this paper we used our own subgroup
of non-pedunculated T1 CRCs to provide a reproducible
method for establishing the immunoscore in non-
pedunculated T1 CRCs. Using the random subgroup, we
first established the mean density per tumor region for each
individual patient, yielding four separate values per patient
(mean density of CD3 IM, CD3 TC, CD8 IM, and CD8
TC). To allow meaningful normalization in a future step,
Fig. 2 Tissue microarray samples collected from the tumor center
and invasive front were immunostained to determine micro-
satellite status, the consensus-molecular-subtype (CMS1 (MSI),
CMS2/3 and CMS4), and the immunoscore. a For each tumor
specimen, H&E stained slides containing tumor center (TC) and
invasive margin (IM) regions were selected by two expert pathologists.
b For each region, three cores (diameter, 0.6mm) were punched out
and were set into a recipient paraffin block using an automated tissue
microarrayer (TMA Grand Master 3D Histech, Sysmex). c TMA core
stained with antibodies against CD3 (tumor in blue; CD3 in brown).
d The density (number of positive cells/surface area analyzed) of
lymphocytes within the tumor center and invasive margin was
quantified with QuPath image analysis. e The immunoscore was based
on the enumeration of two lymphocyte populations (CD3 and CD8).
The consensus-molecular-subtype was based on a panel of five IHC
stains (CDX2, FRMD6, HTR2B, ZEB1, KER) together with micro-
satellite status. #Formula for immunoscore in non-pedunculated T1
CRCs: (((log(CD3 IM+6.35)−6.5185)/0.9117)+((log(CD3 TC
+19.325)−6.4082)/0.8030)+ ((log(CD8 IM+0.3333)−4.4885)/
1.4498)+ ((log(CD8 TC+0.5)−4.1358)/1.4636))/4. If the result is≤-
0.64175 patient is I-Low. If the result is >-0.64175 patient is I-High.
CD3 IM= CD3 density at invasive margin; CD3 TC=CD3 density at
tumor center; CD8 IM= CD8 density at invasive margin; CD8 TC=
CD8 density at tumor center.
K. J. C. Haasnoot et al.
the mean CD3 and CD8 densities of each region were first
natural log-transformed to account for the right-skewedness
of the data across patients (after adding half of the lowest
value for each mean density to allow for zero values). These
natural log mean densities were then transformed to a
standard normal distribution (mean 0, standard deviation 1).
As a final step, the four values of each patient were aver-
aged, and this single score was used to identify the cut-off
values for the 25th and 70th percentile, which were used to
categorize patients into immunoscore groups. Lastly, we
applied the data normalization steps as learned in the sub-
group to categorize cases outside the subgroup into two
groups (≤25th percentile: Low; >25th percentile: High). The
provided formula (Fig. 2) may be used for classifying non-
pedunculated T1 CRCs, and the aforementioned method
can be used to establish cut-off values in different cohorts.
In our Supplementary materials, we also divided patients
into three groups (≤25th percentile: Low; 25th–70th per-
centile: Intermediate; ≥70th percentile: High). In addition, in
our Supplementary materials, we used the classification as
described by Galon et al., in which the immunoscore was
determined to range from I0 when low densities of both cell
types were found in both the TC and IM, to I4 when high
densities were found in both regions [10]. With this method
patients were then further categorized as immunoscore Low
(I0-I1) or High (I2-I4) (Table S1) [8].
Statistical analysis
Baseline characteristics were analyzed using standard
descriptive statistics. We used the subgroup to evaluate the
distribution of MS-status and CMS in patients with T1
CRC. We evaluated the distribution of CMS per tumor
location (left colon vs. right colon vs. rectum) and per
immuno-subtype (I-low vs. I-high). Next, we evaluated the
association between these molecular- and immune-based
scores and the conventional histologic factors (i.e., differ-
entiation grade, lymphovascular invasion, invasion depth,
and tumor budding) with Fisher’s exact test. Per histologic
factor, patients with unknown status for this factor were
excluded from the analysis.
We used a Cox proportional hazard approach weighted
by Prentice’s method to account for the case-cohort sam-
pling to evaluate whether MS-status (MSI vs. MSS), CMS
(CMS4 vs. CMS1/2/3) and immuno-subtypes (I-low vs. I-
high) were associated with adverse outcome (LNM and
recurrent cancer) [21]. Multivariable analysis was per-
formed with adjustment for conventional histologic risk
factors. Results are reported as hazard ratios (HRs) and
95%-CIs. We also calculated HRs for the immunoscore as a
continuous variable (the averaged and normalized natural
log-transformed mean densities of each patient), assuming
linearity as the number of events was too limited to
meaningfully evaluate non-linearity (Supplementary
materials).
GraphPad Prism version 8.01 (GraphPad Software Inc.,
San Diego, CA, USA) was used to draw figures. IBM SPSS
Statistics version 25 (SPSS Inc., Chicago, IL, USA) and R
version 3.5.1 were used for the selection of the 50% sub-
group and statistical analysis respectively. The random
subgroup was drawn using a random number generator,
without oversampling or matching based on any clin-
icopathological variables. It can, therefore, be considered as
an accurate representation of the patient mix of the full
cohort. A two-sided p value < 0.05 was considered sig-
nificant for all tests.
Results
Study population
We identified 651 patients with non-pedunculated T1 CRC
treated with surgery within the participating hospitals, with
a median follow-up time of 44 months (Interquartile range
(IQR) 17–78). The baseline characteristics of the full cohort
and the random subgroup were comparable (Table 1). After
Table 1 Baseline characteristics of the full cohort and random






Male gender, n (%) 185 (55.6) 344 (52.8)
Age in years, median (IQR) 71 (64–77) 70 (64–77)
Missing, n 0 2
Tumor size in mm, median
(IQR)
25 (15–40) 25 (15–40)
Missing, n 21 45
Tumor location, n (%)
Right-sided colon 108 (32.4) 210 (32.3)
Left-sided colon 169 (50.8) 317 (48.7)
Rectum 56 (16.8) 124 (19.0)
Treatment, n (%)
Primary surgery 246 (73.9) 471 (72.4)
Secondary surgery 87 (26.1) 180 (27.6)
Year of diagnosis, n (%)
2000–2005 90 (27.0) 168 (25.8)
2006–2010 126 (37.8) 248 (38.1)
2011–2014 117 (35.1) 235 (36.1)
Nr. of retrieved lymph nodes,
median (IQR)
8 (4–12) 8 (4–13)
Follow-up time in months,
median (IQR)
45 (18-80) 44 (17–78)
IQR interquartilerange.
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the exclusion of ineligible patients or tumor material, a final
subgroup of 223 patients and a final case-cohort of 261
patients remained eligible for analysis (Fig. 1).
We used the case-cohort to evaluate whether MS-status,
CMS, and immunoscore were associated with adverse
outcome. The case-cohort consisted of 198 non-cases
(without an event) and 63 cases, 46 patients with LNM
(10.0% of the full cohort), and 22 patients with recurrent
cancer (4.8% of the full cohort). Five of these patients with
LNM also developed recurrent cancer. Of 22 patients with
recurrent cancer, nine patients had local, eight patients had
distant and five patients had both local and distant
recurrence.
Distribution of molecular subtypes and
Immunoscore
We evaluated the distribution of MS-status, CMS, and
immunoscore in the subgroup. Among 223 patients, 7.2%
were identified as CMS1 according to their MSI status,
91.0% of patients as CMS2/3, and 1.8% as CMS4 (Table 2).
CMS1 tumors were significantly more often located in the
right-sided colon (81.3% right-sided vs. 18.8% left-sided,
p < 0.001).
Based on our subgroup we identified cut-off values for
the immunoscore in non-pedunculated T1 CRC classifying
53 patients as I-low (25%) and 159 patients as I-high (75%)
(Table 2). No significant association was observed between
CMS and immunoscore, although all four patients in the
CMS4 group were classified as I-High.
Association with conventional histologic risk factors
The associations between MS-status, the CMS, and the
immunoscore and conventional histologic risk factors (i.e.,
poor differentiation, lymphovascular invasion, deep sub-
mucosal invasion, and high-grade tumor budding) are
shown in Table 2. Tumors with high-grade tumor budding
were classified as I-low more often than tumors with low-
grade tumor budding (37.7% vs. 20.1%, p= 0.02). CMS4
Table 2 Distribution of CMS &
Immunoscore for non-
pedunculated T1 CRCs and
comparison between T1 CRCs
with and without poor
differentiation, lymphovascular
invasion, deep submucosal
invasion and tumor budding

















Location in colorectum <0.0001* 0.48
Right-sided colon 13 (20.0) 50 (76.9) 2 (3.1) 12 (19.4) 50 (80.6)
Left-sided colon 3 (2.5) 117 (96.7) 1 (0.8) 31 (27.4) 82 (72.6)
Rectum 0 (0) 36 (97.3) 1 (2.7) 10 (27.0) 27 (73.0)
CMS vs. Immunoscore – 0.14
CMS1, n= 15 – – – 1 (6.7) 14 (93.3)
CMS 2/3, n= 193 – – – 52 (26.9) 141 (73.1)
CMS 4, n= 4 – – – 0 (0) 4 (100)
Differentiation grade 0.19 0.27
Moderate/good,
n= 167
15 (9.0) 149 (89.2) 3 (1.8) 37 (23.1) 123 (76.9)




Absent, n= 133 13 (9.8) 117 (88.0) 3 (2.3) 31 (24.4) 96 (75.6)




Superficial, n= 23 1 (4.3) 21 (91.3) 1 (4.3) 5 (22.7) 17 (77.3)
Deep, n= 176 13 (7.4) 160 (90.9) 3 (1.7) 39 (23.4) 128 (76.6)
Tumor budding 0.82 0.02
Low-grade, n= 156 13 (8.3) 140 (89.7) 3 (1.9) 30 (20.1) 119 (79.9)
High-grade, n= 57 3 (5.3) 53 (93.0) 1 (1.8) 20 (37.7) 33 (62.3)
Differentiation grade could not be determined in 2 patients, lymphovascular invasion in 3 patients, invasion
depth in 24 patients, and tumor budding in 10 patients.
CMS Consensus Molecular Subtype, MSImicrosatellite instable, I-low Immunoscore Low, I-high
Immunoscore High.
*p value for CMS1 or CMS2/3/4 and left-sided (including rectum) vs. right-sided colon.
aCMS1 subtype was based on MSI-status; CMS2/3 or 4 based on immunohistochemical CMS-classifier.
bInsufficient cores were assessable for CD3/CD8 densities for total Immunoscore (n= 11).
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tumors did not show high-grade tumor budding more often
than other CMS groups (p= 0.82). No correlation was
found between conventional histologic risk factors and
tumors with CMS4 at the invasive margin (Supplementary
Table S2).
Prognostic value of MS-status, CMS classification
and the Immunoscore
At 5 years, 86.4% and 94.1% of MSS (CMS2/3/4) and MSI
(CMS1) patients were event-free. There was a reduced (non-
significant) risk for an adverse outcome in MSI vs. MSS
tumors (HR 0.42, 95%CI 0.10–1.81, p= 0.25) (Fig. 3a).
Adjusted for conventional histologic risk factors (i.e., dif-
ferentiation grade, invasion depth, lymphovascular invasion,
and tumor budding) these results did not change substantially
(adjusted HR 0.52, 95%CI 0.12–2.30, p= 0.39).
The 5-year event-free percentage was 87.5% and 66.7%
for CMS1/2/3 and CMS4 respectively. Compared with
CMS1/2/3, CMS4 was associated with an increased risk for
an adverse outcome (HR 3.56, 95%CI 1.02–12.4, p=
0.046) (Fig. 3b). Adjusted for conventional risk factors,
CMS4 remained associated with an increased risk for an
adverse outcome (adjusted HR 3.97, 95%CI 1.12–14.06,
p= 0.03).
The 5-year event-free percentage was 81.5% and 88.5%
for I-Low and I-High, respectively. A low immunoscore
suggests a (non-significant) increased risk for an adverse
outcome (HR 1.58, 95%CI 0.88-2.83, p= 0.13) (Fig. 3c).
This risk was attenuated by differences in conventional risk
factors between patients with a high and low immunoscore
(adjusted HR 1.30, 95%CI 0.68–2.48, p= 0.43).
Alternative methods for determining the immunoscore
did not result in an improved risk stratification compared
with the method described in our “Methods” section,
although immunoscore as a continuous variable did show an
increased risk for lower scores (HR 0.67, 95%CI 0.63–0.96,
with coefficient: −0.40, p= 0.03; adjusted HR 0.78
(0.53–1.13), with coefficient −0.26, p= 0.18) (Supple-
mentary Table S3 and Fig. S1A and B).
All conventional risk factors (poor differentiation grade,
lymphovascular invasion, deep submucosal invasion, and
Fig. 3 Event-free proportion at 5 years for MS-status, CMS, and
Immunoscore in non-pedunculated T1 CRCs. 5-year event-free
proportion curves for adverse outcome based on the case-cohort
dataset, reweighted to full cohort proportion by taking the random
subgroup sampling fraction into account for (a) MSI (CMS1) vs. MSS
(CMS2/3/4) tumors (b) CMS4 vs CMS1/2/3 tumors (c) I-low (≤25th
percentile) vs. I-high (>25th percentile). Multivariable HR adjusted for
conventional histologic risk factors (differentiation grade, lympho-
vascular invasion, submucosal invasion depth, and tumor budding).
HR Hazard Ratio as calculated with Prentice’s method; MSI micro-
satellite instable, MSS microsatellite stable, CMS Consensus Mole-
cular Subtype, I-low Immunoscore Low, I-high Immunoscore High.
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high-grade tumor budding), showed an increased risk for
adverse outcome, but it reached statistical significance only
for high-grade tumor budding (HR 2.51, 95%CI 1.45–4.36,
p= 0.001) and lymphovascular invasion (HR 1.72, 95%CI
1.01–2.93, p= 0.046). Adjusted for the other conventional
risk factors and new features (MSI, CMS, and immuno-
score), high-grade tumor budding remained associated with
a statistically significant increased risk (adjusted HR 1.98,
95%CI 1.05–3.76, p= 0.04), while for lymphovascular
invasion the risk became less (adjusted HR 1.66, 95%CI
0.90–3.05, p= 0.10) (Table S4).
Because local recurrence may be the result of the surgical
procedure itself and might not reflect aggressive behavior of
the tumor, we calculated the adjusted HRs excluding
patients with local recurrence only (n= 9) and these HRs
were comparable or even stronger than the original ones:
MSI vs. MSS 0.63 (95%CI 0.14–2.80); CMS4 vs. CMS1/2/
3 4.36 (95%CI 1.21–15.6); I-low vs. I-high 1.42 (95%CI
0.72–2.79).
Discussion
In this large multicenter study, we are the first to evaluate
the frequency distribution and the prognostic value of the
MS-status, CMS-classification, and the immunoscore in
patients with non-pedunculated T1 CRC.
In our study, MSI showed a decreased risk and a low
immunoscore an increased risk for adverse outcome,
although both risks did not reach statistical significance.
CMS4 is uncommon in T1 CRC, but if present, it sub-
stantially increases the risk for LNM and recurrent cancer.
Contrary to previous studies evaluating CMS in
advanced CRC, the proportion of CMS4 tumors was much
smaller in our study (23% vs. 1.8%) [3]. This percentage is
more in line with the one seen in adenomas (0–2%)
[22, 23]. We can only speculate about the biology under-
lying this observation. It might be that between the ade-
noma stage and advanced carcinoma stage there is some
point in time at which the CMS of the invasive cells
changes from CMS1/2/3 to CMS4. Another possibility is
that tumors classified as CMS4 grow faster and thus it is
less likely to find them at an early stage because there might
be only a short interval during which a CMS4 tumor resides
in T-stage 1. In that case the tumor stage would reflect
tumor biology rather than the occurrence of conversion of a
subtype. A third explanation could be that a reduced amount
of desmoplastic cancer stroma surrounding early invasive
cancer cells compared with advanced tumors accounts for
fewer T1 CRCs classified as CMS4, because, besides the
tumor cells, the stroma also attributes considerably to the
classification of this subtype [24, 25]. These hypotheses are
all in line with the CMS landmark paper that concluded that
CMS4 tended to be present more often in advanced stages
of diagnosis [3]. In any case, the rarity of CMS4 in T1 CRC
should be taken into account when CMS is applied because
this low incidence makes its value less in clinical decision-
making.
Although a low immunoscore was not statistically sig-
nificantly associated with adverse outcome in our cohort,
the hazard ratio pointed towards an increased risk. This
concurs with the results of a recent meta-analysis in which
I-low was associated with poor prognosis in advanced
tumors [11]. Importantly, we used cut-off values based on
just T1 tumors because lymphocyte counts can vary
between tumor stages [26]. Therefore, the method we used
provides a reproducible and precise manner of determining
immunoscore in non-pedunculated T1 CRCs. Because I-
low was associated with high-grade tumor budding, a strong
predictor of LNM in T1 CRC, the risk for I-low patients
became less in our multivariable analysis [27].
An important finding of this study is that the mesench-
ymal group (CMS4) had a significant risk for adverse out-
come compared with non-CMS4 patients. This finding is in
line with CMS4 patients in studies with advanced CRC, in
which this subgroup also had a worse prognosis compared
with non-CMS4 patients [3]. Our IHC-classifier for CMS
used five IHC-markers to distinguish CMS4 from CMS2/3
and several studies have also related mesenchymal-like
markers with LNM and poor survival. Sugai et al. demon-
strated that the expression of mesenchymal-like markers
was correlated with LNM in T1 CRC. ZEB1, used in their
study, was also used in our CMS-classifier, but other bio-
markers such as Twist1 and α-SMA were not [28]. Also, by
assessing five separate mesenchymal markers in stage II/III
CRC patients, Roseweir et al. showed that patients at risk
for micrometastases and poor survival could be adequately
identified [29]. As such, mesenchymal markers may con-
tribute to risk stratification in CRC, however, due to the low
prevalence of CMS4 in non-pedunculated T1 CRCs, it
seems unlikely that this prognostic marker will contribute
considerably to clinical decision-making in these patients.
This study has some limitations. First, for efficiency
reasons we used a case-cohort design instead of evaluating
the full-cohort, limiting the number of patients within sub-
groups for evaluation of the frequency distribution of the
different classifiers. Thus, the number of patients classified
as CMS1 or CMS4 was low. Nevertheless, we believe that
our cohort is representative for T1 CRC in a Western
population, including all T1 CRC patients from a tertiary
and multiple secondary hospitals between 2000 and 2014.
Only 11 patients in our cohort were detected by the nation
wide screening program for CRC initiated in The Nether-
lands in 2014. CRCs found through screening might have
different tumor biology and behavior [30]. Because of the
small proportion of screen-detected patients in our cohort
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(4.2%), we could not evaluate whether the detection method
may influence the distribution of MSI, CMS or immuno-
score, nor whether the same association with poor outcome
as we observed in an almost exclusively non-screen detec-
ted cohort is present in screen-detected T1 CRCs. Second,
we used TMAs rather than whole tumor slides, risking
sampling error. Nonetheless, earlier studies have shown that
TMA analysis is reliable for determining MS-status, CD8
counts, and our used CMS-classifier [19, 31–33]. Further-
more, by analyzing cores from both the TC and IM, we tried
to reduce sampling bias in heterogeneous tumors, a phe-
nomenon observed by Ubink et al. when comparing multi-
region endoscopic biopsies from CRC resection specimens
[34]. Spatial variation in stromal composition throughout
the tumor could influence subtype stratification and multi-
region testing for CMS4 is needed, which could be pro-
blematic in T1 CRC when tissue may be scarce. Third,
although we were able to distinguish CMS1 (MSI) and
CMS4 (mesenchymal)-type tumors, the classifier does not
discriminate between CMS2 and CMS3. On the other hand,
CMS1 and CMS4, are the two groups that discriminate best
regarding prognosis and are therefore the most important
subtypes to distinguish [3, 19]. The use of this validated
IHC-based classifier, makes it more readily available in the
pathology department and clinical practice as transcription-
based methods are yet to be widely implemented. Other
methods for CMS-subtyping, such as RNA-analysis are
expensive, time-consuming, and not routinely performed in
clinical practice compared with IHC-analysis [4, 19, 35].
Furthermore, not all of these analyses can be easily per-
formed on FFPE, still the golden standard for processing
tissue in pathology departments, especially when tumor
material is scarce as in T1 CRC tumors [36]. Lastly, even
though our cohort is one of the largest T1 CRC series, and
despite using a large sampling fraction of 50% of the total
cohort, this revised cohort still has limited power to detect
weak to intermediate prognostic factors such as I-low or
MSI; for this much larger cohorts would be needed. Com-
bining large T1 CRC cohorts in future studies might clarify
whether such effects exists in T1 CRC.
In conclusion, this is the first study performed in a large
cohort of patients with non-pedunculated T1 CRC focusing
on promising prognostic markers, namely MS-status, CMS,
and immunoscore based on immunohistochemical analysis.
Albeit non-significant, our data showed that MSI is asso-
ciated with a decreased and I-low with an increased risk for
adverse outcome. CMS4 is uncommon in non-pedunculated
T1 CRC, but if present, it increased the risk for LNM and
recurrence of cancer significantly in our study. These results
should be taken into account when molecular- and immune-
based scores are being implemented in clinical practice
for CRC.
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